Athira Pharma
Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.
Facts
- HQ
- Seattle
- Sectors
- Biopharmaceuticals, Biotech, Pharmaceuticals
- Employees
- 30
- Stage
- Series B
Is this your organization? Claim it
Archive: The Long Run: Creating a Life Science Startup (Fundamentals for Startups)
(https://comotion.uw.edu) Originally streamed Friday, February 5th, 2021 from 12-1 pm, this Fundamentals for Startups featured Leen Jawas, CEO of Athira Pharma (https://www.athira.com/about-athira/) presenting: "The Long Run: Creating a Life Science Startup" Dr. Leen Kawas has served as Athira Pharma’s CEO and as a member of the board of directors since January 2014. Previously, Dr. Kawas served as Athira’s vice president. Dr. Kawas serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Association – Washington Chapter Board. She also served as the co-chair of the International Alzheimer's…
People
-
Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer